Mechanisms and Management of Right-Sided Heart Failure: A Focused Review

Introduction

Right-sided heart failure is a condition where the right ventricle of the heart loses its ability to pump blood effectively.

Normal Mechanism- The right ventricle’s primary job is to receive deoxygenated blood returning from the body (via the veins) and pump it into the lungs to get oxygen.  When the right ventricle weakens, blood backs up in the veins, causing fluid to leak into surrounding tissues and organs. This is the reason that right sided heart failure is often characterized by fluid buildup (congestion) in the body, not just the lungs. (1)

Epidemiology

Right heart failure rarely occurs in isolation. It is most commonly a consequence of left heart failure (the majority of cases), pulmonary hypertension, or right ventricular (RV) myocardial disease.

• Left Heart Failure

In patients reduced ejection fraction (HFrEF), some degree of RV dysfunction is present in 30–50% of cases. While in patients with preserved ejection fraction (HFpEF), RV dysfunction is affecting approximately 30–40% of patients, particularly those with pulmonary hypertension (1).

• Pulmonary Hypertension

In this condition RV failure is the ultimate cause of death. At diagnosis, up to 15–20% of PAH patients already have signs of RV dysfunction

Prognosis

The prognosis of RHF is consistently worse than that of isolated left heart failure, and RV dysfunction is an independent predictor of mortality across multiple cardiovascular diseases.

• Heart failure with reduced ejection fraction (HFrEF)

o   In a pooled analysis of major HF trials, the presence of RV dysfunction (by echo or MRI) was associated with a 1.5- to 2-fold increase in all-cause mortality and heart failure hospitalization, independent of LVEF

o   5-year mortality in HFrEF with RV dysfunction (50–60%) Vs without RV dysfunction (30–35%) (2).

• Pulmonary arterial hypertension (PAH)

o   The REVEAL registry stated patients with PAH and moderate-to-severe RV dysfunction have a 1-year mortality of 20–25% compared to 5–10% with preserved RV function.

o   Markers of RV failure (elevated right atrial pressure, low cardiac index, RV enlargement) are incorporated into prognostic risk scores (ESC/ERS risk table) (3).

• Acute RV failure (e.g., RV infarction)

o   In acute inferior MI with RV involvement, in-hospital mortality is 5–10% higher than without RV involvement.

o   Long-term prognosis: 5 year survival is 75% if no residual LV dysfunction, but can fall to 50% if LVEF is also reduced (1).

Pathophysiology

Normal right ventricular function depends on a delicate balance between five key physiological components: preload (venous return), afterload (pulmonary artery pressures), myocardial contractility, pericardial compliance, and interventricular dependence. A change in any one of these can precipitate RV failure.

Acute right ventricular failure

1. Pressure overload (increased afterload) (4)

• Caused by: pulmonary embolism, acute left heart failure, or any sudden rise in pulmonary artery pressures.

• The RV has a thin, compliant wall and is poorly suited to abrupt afterload increases. Unlike the LV, it cannot quickly adapt.

• Even a small rise in afterload can sharply reduce stroke volume.

• RV ejection fraction is inversely related to pulmonary artery systolic pressure, a relationship not seen in the LV.

• Clinical takeaway: Managing afterload is critical in treating RV dysfunction.

2. Volume overload (increased preload)

• Caused by: LVAD implantation, aggressive fluid resuscitation, or high-output states like sepsis.

• In contrast to pressure overload, the RV handles volume overload reasonably well through heterometric adaptation (Frank-Starling mechanism) (5).

• However, excessive volume can still lead to progressive dilatation and eventual dysfunction.

3. Reduced contractility

• Caused by: RV infarction, myocarditis, or arrhythmias.

• Leads to lower stroke volume and RV dilatation.

• This often triggers a downward spiral: dilatation → tricuspid regurgitation → more dilatation → compression of the LV (5).

4. Interventricular dependence

This refers to the mechanical influence the two ventricles have on each other.

• Systolic interaction: LV contraction contributes up to 40% of RV systolic pressure. A weak LV therefore directly impairs RV function.

• Diastolic interaction: Ventricles compete for space within the pericardium. This occurs in tamponade (non-compliant pericardium) or when RV pressure overload crowds the LV, reducing cardiac output (6).

  
  

Chronic Right Ventricular Failure

1. Pressure overload (chronic increased afterload)

• Causes: Chronic left heart failure, pulmonary hypertension (any cause), chronic thromboembolic disease.

• Prognosis: Patients with RV failure driven by chronic pressure overload have a poor long-term outlook.

2. Volume overload

• Causes: Congenital heart disease with shunts (e.g., atrial septal defect), chronic right-sided valvular regurgitation.

• Natural history:

  • Compensatory phase: RV hypertrophy and fibrosis develop.

  • Progression: Metabolic changes occur (mitochondrial dysfunction, further fibrosis), leading to progressive RV dilatation and worsening function.

• Unlike in acute settings, chronic volume overload eventually becomes maladaptive.

3. Interventricular dependence in chronic disease

• As the RV dilates and fails, it physically compresses the LV, reducing left-sided cardiac output.

• Special case – chronic pericardial disease: Here, LV output falls not because of RV dilatation, but because both ventricles compete for space within a fixed, non-expandable pericardial sac (e.g., constrictive pericarditis).

4. Primary myocardial disease (reduced contractility)

Several cardiomyopathies directly impair RV contractility without necessarily causing pressure or volume overload first:

• Arrhythmogenic right ventricular dysplasia (ARVD)

• Dilated cardiomyopathy (biventricular involvement)

• Long-term sequelae of myocarditis

Management Strategies

The management of RVF depends on the underlying mechanism, the overall management requires a similarly thorough diagnostic evaluation and there is considerable overlap between the therapeutic approaches (5).

Treatment of Acute Right Heart Failure

1. Treat the underlying cause

• RV infarction → reperfusion + cautious fluid administration

• Pulmonary embolism → anticoagulation; consider thrombolysis or clot retrieval if severe.

• Critically ill patients → careful volume management; avoid high ventilator pressures (they increase RV afterload).

2. Optimize preload (volume status)

• Target central venous pressure: 8–12 mmHg

• If overloaded: high-dose furosemide infusion; add thiazides if needed; consider renal replacement therapy if diuretic-resistant.

• If underfilled (e.g., RV infarct): give small, cautious fluid boluses

• Avoid overloading—excessive volume dilates the RV, worsens tricuspid regurgitation, and compresses the LV (6).

3. Reduce afterload (pulmonary vasodilation)

• Inhaled agents (preferred): nitric oxide (5–20 ppm) or epoprostenol—no systemic hypotension (7).

• Intravenous agents: milrinone (also improves contractility but may cause hypotension).

• Oral agents (select cases): phosphodiesterase-5 inhibitors (e.g., sildenafil) after LVAD implantation(8).

• Caution: Do not use pulmonary vasodilators in isolated post-capillary PH unless left-sided issues are addressed first (risk of pulmonary edema.

4. Enhance RV contractility

• Dobutamine – shorter half-life, mild vasodilation

• Milrinone – more potent vasodilator; adjust dose for renal function (9).

• Levosimendan – improves contractility; supported by data in various RV failure settings (10).

• Norepinephrine – may improve RV-PA coupling; useful alongside inotropes

Note: Avoid inotropes if RV failure is driven by active ischemia or arrhythmias.

Treatment of Chronic Right Heart Failure

1. Volume management

• Diuretics are the cornerstone (loop diuretics ± thiazides) (11).

• Goal: relieve congestion without reducing preload too much.

• Monitor renal function closely—over-diuresis can cause pre-renal failure.

2. Afterload management (cause-specific) (11)

Cause	Approach
·       LV failure with reduced EF	Guideline-directed therapy: beta-blockers, ACEi/ARB (ARNI are preferred over these in the recent years), MRA, ARNI, SGLT2 inhibitors
·       Group I PAH	Diuretics, oxygen (if pO2 <8 kPa), CCBs, PDE5 inhibitors (e.g., sildenafil), prostacyclin analogues, endothelin receptor antagonists
·       Group IV CTEPH	Lifelong anticoagulation; consider pulmonary endarterectomy, balloon pulmonary angioplasty (BPA) at specialist center
·       Congenital heart disease	Refer to adult congenital heart disease team

3. Device therapy (when medical therapy fails)

Short-term support:

• VA-ECMO – supports both ventricles; reduces RV preload and wall tension (12).

• PROTEK DUO – percutaneous cannula (jugular vein); drains RA, returns to PA; allows mobilization (13).

• IMPELLA RP – microaxial pump for acute RV failure (post-LVAD, post-MI, post-cardiotomy) needs current market status check (14).

• CentriMag – magnetically levitated pump; longer support; often requires surgical implantation.

Long-term support:

• RVAD (e.g., HeartMate 3) – used off-label for RV support; reserve for cases unlikely to recover quickly (15).

• Total Artificial Heart (SynCardia) – biventricular replacement; bridge to transplantation (16).

4. Heart transplantation

• Consider when all other options fail and no reversible causes remain.

• Indicated mainly for arrhythmogenic RV cardiomyopathy or extensive RV ischemia.

• Preoperative RVAD use is associated with higher post-transplant mortality (17).

Conclusion

Right‑heart failure (RHF) is a common, high‑mortality syndrome that rarely occurs in isolation and is most often driven by left‑sided disease, pulmonary hypertension, or primary right‑ventricular pathology. Across heart‑failure phenotypes, the presence of right‑ventricular dysfunction markedly worsens prognosis, with a two‑fold increase in mortality and hospitalization risk. The pathophysiology of RHF is uniquely dictated by the interplay of preload, afterload, myocardial contractility, pericardial compliance, and interventricular dependence; disturbances in any of these domains can precipitate acute decompensation or chronic progression.

Early identification through integrated clinical assessment, advanced echocardiography, cardiac magnetic resonance, and hemodynamic monitoring is essential because therapeutic success hinges on targeting the dominant mechanistic driver. Acute management prioritizes treating the inciting cause, judicious fluid optimization, afterload reduction with inhaled pulmonary vasodilators, and inotropic support when needed. Chronic care focuses on sustained volume control, disease‑specific afterload reduction (e.g., guideline‑directed HFrEF therapy, PAH‑targeted agents), and timely escalation to mechanical circulatory support or transplantation for refractory cases.

Future research should aim to refine risk stratification using multimodal biomarkers and imaging, develop RV‑specific pharmacotherapies, and expand the evidence base for percutaneous RV assist devices. A multidisciplinary approach—linking heart‑failure specialists, pulmonologists, surgeons, and imaging experts—will be pivotal in improving outcomes for patients with this complex and often under‑recognized condition.

References

1) Monteagudo-Vela, María, et al. “Right Ventricular Failure: Current Strategies and Future Development.” Frontiers in Cardiovascular Medicine, vol. 10, Apr. 2023, p. 998382. DOI.org (Crossref), https://doi.org/10.3389/fcvm.2023.998382.

2)Schneider, Robert H., et al. “Editorial Commentary on AHA Scientific Statement on Meditation and Cardiovascular Risk Reduction.” Journal of the American Society of Hypertension, vol. 12, no. 12, Dec. 2018, pp. e57–58. DOI.org (Crossref), https://doi.org/10.1016/j.jash.2018.11.005.

3) Camm, A. John, et al. The ESC Textbook of Cardiovascular Medicine. 3rd ed., Oxford University Press, 2018. DOI.org (Crossref), https://doi.org/10.1093/med/9780198784906.001.0001.

4) Ortiz-Jaimes, G. E., et al. “Real Time Bedside Echocardiography-Guided Mechanical Ventilation Optimization in a Patient With Carcinoid Heart Disease, Right Ventricular Failure, and Severe ARDS.” B104. TOP CASE REPORTS OF MECHANICAL VENTILATION/ARDS FROM THE PAST YEAR, 2023, pp. A4338–A4338. DOI.org (Crossref), https://doi.org/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A4338.

5)Konstam, Marvin A., et al. “Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association.” Circulation, vol. 137, no. 20, May 2018. DOI.org (Crossref), https://doi.org/10.1161/CIR.0000000000000560.

6)Santamore, William P., and Louis J. Dell’Italia. “Ventricular Interdependence: Significant Left Ventricular Contributions to Right Ventricular Systolic Function.” Progress in Cardiovascular Diseases, vol. 40, no. 4, Jan. 1998, pp. 289–308. DOI.org (Crossref), https://doi.org/10.1016/S0033-0620(98)80049-2.

7)Wasson, Sanjeev, et al. “The Role of Nitric Oxide and Vasopressin in Refractory Right Heart Failure.” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 9, no. 1, Mar. 2004, pp. 9–11. DOI.org (Crossref), https://doi.org/10.1177/107424840400900i102.

8) Baker, William L., et al. “Systematic Review of Phosphodiesterase‐5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation.” Artificial Organs, vol. 40, no. 2, Feb. 2016, pp. 123–28. DOI.org (Crossref), https://doi.org/10.1111/aor.12518.

9)Grose, Richard, et al. “Systemic and Coronary Effects of Intravenous Milrinone and Dobutamine in Congestive Heart Failure.” Journal of the American College of Cardiology, vol. 7, no. 5, May 1986, pp. 1107–13. DOI.org (Crossref), https://doi.org/10.1016/S0735-1097(86)80231-5.

10)Hansen, Mona Sahlholdt, et al. “Levosimendan in Pulmonary Hypertension and Right Heart Failure.” Pulmonary Circulation, vol. 8, no. 3, July 2018, pp. 1–7. DOI.org (Crossref), https://doi.org/10.1177/2045894018790905.

11) Jerónimo, Adrián, et al. “Malaposición del stent por vasoespasmo en el síndrome coronario agudo.” Revista Española de Cardiología, vol. 75, no. 9, Sept. 2022, p. 764. DOI.org (Crossref), https://doi.org/10.1016/j.recesp.2022.01.002.

12)Grant, Christian, et al. “ECMO and Right Ventricular Failure: Review of the Literature.” Journal of Intensive Care Medicine, vol. 36, no. 3, Mar. 2021, pp. 352–60. DOI.org (Crossref), https://doi.org/10.1177/0885066619900503.

13) ProtekDuo Kit. https://www.livanova.com/advanced-circulatory-support/en-us/protekduo-kit. Accessed 13 Apr. 2026.

14) Monteagudo‐Vela, María, et al. “Initial Experience with Impella RP in a Quaternary Transplant Center.” Artificial Organs, vol. 44, no. 5, May 2020, pp. 473–77. DOI.org (Crossref), https://doi.org/10.1111/aor.13610.

15) Bellavia, Diego, et al. “Prediction of Right Ventricular Failure After Ventricular Assist Device Implant: Systematic Review and Meta-Analysis of Observational Studies.” European Journal of Heart Failure, vol. 19, no. 7, July 2017, pp. 926–46. DOI.org (Crossref), https://doi.org/10.1002/ejhf.733.

16)Banner University Hospital, Tucson, AZ, et al. “Total Artificial Heart Update.” Surgical Technology Online, June 2021. DOI.org (Crossref), https://doi.org/10.52198/21.STI.38.CV1449.

17) Bianco, Juan C., et al. “Heart Transplantation in Patients >60 Years: Importance of Relative Pulmonary Hypertension and Right Ventricular Failure on Midterm Survival.” Journal of Cardiothoracic and Vascular Anesthesia, vol. 32, no. 1, Feb. 2018, pp. 32–40. DOI.org (Crossref), https://doi.org/10.1053/j.jvca.2017.09.017.

Assessed and Endorsed by the MedReport Medical Review Board